Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
J Endocrinol Invest ; 47(2): 345-356, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37466810

RESUMO

PURPOSE: This study aimed to assess the real-world management of achondroplasia in Italy. METHODS: Two online surveys addressed to (1) parents/caregivers of individuals with achondroplasia and (2) Italian clinicians managing individuals with achondroplasia were conducted to assess real-world perspectives on achondroplasia management. Both surveys collected data on either patient or clinician demographics, details on diagnoses and referrals, disease complications, and views/experiences with limb lengthening surgery. RESULTS: In total, 42 parents/caregivers and 19 clinicians (from 18 hospitals) completed the surveys. According to parents/caregivers, achondroplasia diagnosis was most commonly made in the third trimester of gestation (55% of respondents), with a genetic test performed to confirm the diagnosis in all but one case. In contrast, the clinicians indicated that, while achondroplasia was typically suspected during the prenatal period (78%), diagnosis was more frequently confirmed postnatally (72%). Parents/caregivers reported that the greatest impact of achondroplasia-related complications occurred in their children between the ages of 2-5 years. The most significant complications were otitis, sleep apnoea, stenosis of the foramen magnum or pressure on the spinal cord, and hearing difficulties. Lengthening surgery had been presented as a treatment option to 92% of responding parents/caregivers, with 76% of clinicians viewing surgery favourably. Typically, clinicians' reasons for suggesting limb lengthening surgery were to improve patient quality of life, increase patient autonomy and self-acceptance, improve trunk-limb disproportion, short stature and walking, and ensure that all possible treatment options had been presented to the parents/caregivers. CONCLUSION: This survey provides insight into the real-world management of individuals with achondroplasia in Italy.


Assuntos
Acondroplasia , Qualidade de Vida , Criança , Humanos , Pré-Escolar , Cuidadores , Acondroplasia/diagnóstico , Acondroplasia/epidemiologia , Acondroplasia/terapia , Inquéritos e Questionários , Pais
2.
J Neurooncol ; 157(3): 551-559, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35397759

RESUMO

PURPOSE: Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients. METHODS: We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints). RESULTS: Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice. In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI). Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months. Side effects were mainly mild (grade 1-2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence. CONCLUSIONS: This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.


Assuntos
Neoplasias Encefálicas , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Epilepsias Parciais , Epilepsia , Acetamidas , Anticonvulsivantes/uso terapêutico , Neoplasias Encefálicas/complicações , Neoplasias Encefálicas/tratamento farmacológico , Epilepsias Parciais/complicações , Epilepsias Parciais/tratamento farmacológico , Epilepsia/complicações , Epilepsia/etiologia , Humanos , Lacosamida/uso terapêutico , Qualidade de Vida , Estudos Retrospectivos , Convulsões/tratamento farmacológico , Resultado do Tratamento
3.
J Endocrinol Invest ; 44(1): 145-151, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-32378143

RESUMO

PURPOSE: 46, XY disorders (or differences) of sex development (DSD) are a group of clinical conditions with variable genetic background; correct diagnosis is often difficult, but it permits to optimize the management. The aim of this study is to identify clinical and genetics features of a group of women with 46, XY DSD to define some issues characterizing people with 46, XY DSD in Italy. METHODS: Retrospective analysis of girls and women with 46, XY DSD and female phenotype evaluated between year 2000 and 2016, performed by anonymised database, focusing on the clinical features and management, including presentation, first diagnostic suspect, gonadal surgery and molecular diagnostic delay. RESULTS: A total of 84 records were collected (mean age at clinical presentation: 9.1 ± 7.9 years; mean age at definitive diagnosis: 20.1 ± 15.0 years). Complete androgen insensitivity syndrome was the most common diagnosis (60%). Only 12 patients (14.3%) did not receive a molecular diagnosis. Early misdiagnoses frequently occurred; diagnostic delay was 10.2 ± 11.2 years, being reduced in patients presenting from 2007 to 2016. The discordance between genotypic and phenotypic sex during pregnancy or at birth determined early reason for referral in a considerable percentage (4.9%). CONCLUSION: Misdiagnosis and long diagnostic delays are present in females with 46, XY DSD in Italy, but the new genetic techniques permit faster right diagnoses in the last years. The centralization in dedicated third level units permits to reduce the number of patients without a molecular diagnosis, allowing better clinical management and appropriate genetic counselling.


Assuntos
Transtornos do Desenvolvimento Sexual/diagnóstico , Gônadas/patologia , Adulto , Criança , Transtornos do Desenvolvimento Sexual/genética , Feminino , Seguimentos , Gônadas/metabolismo , Humanos , Cariótipo , Fenótipo , Prognóstico , Estudos Retrospectivos , Adulto Jovem
4.
Gynecol Endocrinol ; 36(10): 938-940, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33021135

RESUMO

Objective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2 months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173 ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings.


Assuntos
Anticorpos Heterófilos , Erros de Diagnóstico , Gonadotropinas/sangue , Menopausa/sangue , Animais , Feminino , Cabras/imunologia , Humanos , Pessoa de Meia-Idade
5.
Skeletal Radiol ; 47(1): 131-136, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28889228

RESUMO

Calcific tendinopathy of the rotator cuff is a common cause of shoulder pain. Inflammation of the rotator cuff tendons may be complicated by adjacent bone erosion and subsequent migration of calcific deposits within the bone resulting in marrow inflammation. Bone marrow involvement is not readily visible using X-ray and ultrasound (US) and further testing is necessary. Magnetic resonance imaging (MRI) is a highly sensitive technique that can detect a focal bone T1 and T2-weighted hypointensity with bone marrow edema-like signal and cortical erosion. These findings can mislead the radiologist by suggesting an infectious or neoplastic lesion, often requiring further evaluation with computed tomography (CT) and biopsy. We report two cases of patients with shoulder pain in which different radiological approaches were used with pathological confirmation in one of them. In the first case, MRI revealed significant bone involvement in the head of the humerus and cortical erosion of the greater tuberosity. A CT examination and a biopsy was necessary for a final diagnosis of inflammatory bone reaction from intraosseous migration of tendinous calcifications. In the second case, similar MRI findings prompted re-evaluation of imaging to make a diagnosis of intraosseous migration of tendinous calcifications, obviating the need to perform CT and biopsy. We illustrate MRI signs of this complication that we think would allow to narrow the differential diagnosis potentially avoiding biopsy and additional CT examinations.


Assuntos
Calcinose/diagnóstico por imagem , Manguito Rotador/diagnóstico por imagem , Tendinopatia/diagnóstico por imagem , Adulto , Calcinose/patologia , Calcinose/terapia , Tratamento Conservador , Meios de Contraste , Diagnóstico Diferencial , Feminino , Humanos , Biópsia Guiada por Imagem , Imageamento por Ressonância Magnética , Manguito Rotador/patologia , Tendinopatia/patologia , Tendinopatia/terapia , Tomografia Computadorizada por Raios X , Ultrassonografia
6.
Pharmacogenomics J ; 18(3): 422-430, 2018 05 22.
Artigo em Inglês | MEDLINE | ID: mdl-28719598

RESUMO

We investigated in ninety Caucasian pediatric patients the impact of the main polymorphisms occurring in CYP3A, CYP2D6, ABCB1 and ABCG2 genes on second-generation antipsychotics plasma concentrations, and their association with the occurrence of adverse drug reactions. Patients with the CA/AA ABCG2 genotype had a statistically significant lower risperidone plasma concentration/dose ratio (Ct/ds) (P-value: 0.007) and an higher estimated marginal probability of developing metabolism and nutrition disorders as compared to the ABCG2 c.421 non-CA/AA genotypes (P-value: 0.008). Multivariate analysis revealed that the ABCG2 c.421 CA/AA genotype was found associated to a higher hazard (P-value: 0.004) of developing adverse drug reactions classified as metabolism and nutrition disorders. The ABCB1 2677TT/3435TT genotype had a statistically significant lower aripiprazole Ct/ds if compared with patients with others ABCB1 genotypes (P-value: 0.026). Information obtained on ABCB1 and ABCG2 gene variants may result useful to tailor treatments with these drugs in Caucasian pediatric patients.


Assuntos
Aripiprazol/sangue , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética , Risperidona/sangue , Esquizofrenia/sangue , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/genética , Adolescente , Aripiprazol/administração & dosagem , Criança , Pré-Escolar , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP3A/genética , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/sangue , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Feminino , Genótipo , Humanos , Masculino , Proteínas de Neoplasias/genética , Olanzapina/administração & dosagem , Olanzapina/sangue , Pediatria/tendências , Polimorfismo Genético , Fumarato de Quetiapina/administração & dosagem , Fumarato de Quetiapina/sangue , Risperidona/administração & dosagem , Esquizofrenia/tratamento farmacológico , Esquizofrenia/patologia , Adulto Jovem
7.
Eye (Lond) ; 31(10): 1417-1426, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28524885

RESUMO

PurposeTo evaluate ocular surface parameters before and after hematopoietic stem cell transplantation (HSCT) and to correlate them with clinical and transplant variables.MethodsThis is a retrospective analysis of data from 93 patients affected by hematological malignancies undergoing HSCT. Values from Ocular Surface Disease Index, Schirmer test, Break-up Time, ocular surface staining, and Meibomian Gland Dysfunction score obtained before HSCT and 3-6 months after were retrieved from charts. Diagnosis and staging of dry eye (DE) disease was performed according to Dry Eye WorkShop criteria. Graft-versus-host-disease (GVHD) was classified according to the NIH criteria. Odds ratios for DE onset after HSCT were estimated for demographic, ocular, hematological and transplant variables.ResultsDE was diagnosed before HSCT in 50 (53%) of the patients, mostly of hyperevaporative profile. After HSCT, all ocular parameters significantly worsened with no change in DE profile. A 51% incident cases (22 of the 43 non-DE subjects) were reported. Increasing recipient age and female sex, higher CD34+ cells infused, donor-recipient sex mismatch (males receiving from females), related donors, and peripheral blood cells as stem cell source were associated with a significant higher incidence of DE after HSCT. Systemic chronic GVHD was diagnosed in 42% while ocular GVHD in 35.5% of the patients, which decreased to 12% when taking into account only incident cases.ConclusionsHigh DE prevalence was shown already before HSCT. A pre-HSCT ocular surface assessment is recommended for early DE diagnosis and treatment. This new protocol also influences the prevalence of ocular GVHD.


Assuntos
Túnica Conjuntiva/patologia , Síndromes do Olho Seco/diagnóstico , Doença Enxerto-Hospedeiro/diagnóstico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Glândulas Tarsais/patologia , Medição de Risco , Adolescente , Adulto , Técnicas de Diagnóstico Oftalmológico , Síndromes do Olho Seco/epidemiologia , Síndromes do Olho Seco/etiologia , Feminino , Doença Enxerto-Hospedeiro/complicações , Doença Enxerto-Hospedeiro/epidemiologia , Neoplasias Hematológicas/terapia , Humanos , Incidência , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Fatores de Risco , Transplante Homólogo , Adulto Jovem
8.
Eur Heart J ; 36(25): 1590-600, 2015 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-25904764

RESUMO

AIM: Constitutive genetic deletion of the adaptor protein p66(Shc) was shown to protect from ischaemia/reperfusion injury. Here, we aimed at understanding the molecular mechanisms underlying this effect in stroke and studied p66(Shc) gene regulation in human ischaemic stroke. METHODS AND RESULTS: Ischaemia/reperfusion brain injury was induced by performing a transient middle cerebral artery occlusion surgery on wild-type mice. After the ischaemic episode and upon reperfusion, small interfering RNA targeting p66(Shc) was injected intravenously. We observed that post-ischaemic p66(Shc) knockdown preserved blood-brain barrier integrity that resulted in improved stroke outcome, as identified by smaller lesion volumes, decreased neurological deficits, and increased survival. Experiments on primary human brain microvascular endothelial cells demonstrated that silencing of the adaptor protein p66(Shc) preserves claudin-5 protein levels during hypoxia/reoxygenation by reducing nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production. Further, we found that in peripheral blood monocytes of acute ischaemic stroke patients p66(Shc) gene expression is transiently increased and that this increase correlates with short-term neurological outcome. CONCLUSION: Post-ischaemic silencing of p66(Shc) upon reperfusion improves stroke outcome in mice while the expression of p66(Shc) gene correlates with short-term outcome in patients with ischaemic stroke.


Assuntos
Lesões Encefálicas/prevenção & controle , Inativação Gênica/fisiologia , Traumatismo por Reperfusão/prevenção & controle , Proteínas Adaptadoras da Sinalização Shc/genética , Acidente Vascular Cerebral/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Animais , Barreira Hematoencefálica/fisiologia , Estudos de Casos e Controles , Células Cultivadas , Claudina-5/efeitos dos fármacos , Células Endoteliais/fisiologia , Feminino , Expressão Gênica , Técnicas de Silenciamento de Genes , Humanos , Infarto da Artéria Cerebral Média , Pós-Condicionamento Isquêmico/métodos , Masculino , Camundongos Endogâmicos C57BL , Microcirculação/fisiologia , Pessoa de Meia-Idade , RNA Mensageiro/metabolismo , RNA Interferente Pequeno/farmacologia , Espécies Reativas de Oxigênio/farmacologia , Proteínas Adaptadoras da Sinalização Shc/fisiologia , Proteína 1 de Transformação que Contém Domínio 2 de Homologia de Src , Resultado do Tratamento
9.
Transl Med UniSa ; 5: 7-13, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23905076

RESUMO

Osteoporosis and avascular necrosis (AVN) are long-lasting and debilitating complications of hematopoietic stem cell transplantation (HSCT). We describe the magnitude of bone loss, AVN and impairment in osteogenic cell compartment following autologous (auto) and allogeneic (allo) HSCT, through the retrospective bone damage revaluation of 100 (50 auto- and 50 allo-HSCT) long-term survivors up to 15 years after transplant. Current treatment options for the management of these complications are also outlined. We found that auto- and allo-HSCT recipients show accelerated bone mineral loss and micro-architectural deterioration during the first years after transplant. Bone mass density (BMD) at the lumbar spine, but not at the femur neck, may improve in some patients after HSCT, suggesting more prolonged bone damage in cortical bone. Phalangeal BMD values remained low for even more years, suggesting persistent bone micro-architectural alterations after transplant. The incidence of AVN was higher in allo-HSCT recipients compared to auto-HSCT recipients. Steroid treatment length, but not its cumulative dose was associated with a higher incidence of bone loss. Allo-HSCT recipients affected by chronic graft versus host disease seem to be at greater risk of continuous bone loss and AVN development. Reduced BMD and higher incidence of AVN was partly related to a reduced regenerating capacity of the normal marrow osteogenic cell compartment. Our results suggest that all patients after auto-HSCT and allo-HSCT should be evaluated for their bone status and treated with anti-resorptive therapy as soon as abnormalities are detected.

10.
J Neurointerv Surg ; 2(1): 74-9, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21990564

RESUMO

OBJECTIVE To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis (IAT) compared with standard intravenous thrombolysis (IVT) for acute ischemic stroke. METHODS Eligible patients with ischemic stroke, who were devoid of contraindications, started IVT within 3 h or IAT as soon as possible within 6 h. Patients were randomized within 3 h of onset to receive either intravenous alteplase, in accordance with the current European labeling, or up to 0.9 mg/kg intra-arterial alteplase (maximum 90 mg), over 60 min into the thrombus, if necessary with mechanical clot disruption and/or retrieval. The purpose of the study was to determine the proportion of favorable outcome at 90 days. Safety endpoints included symptomatic intracranial hemorrhage (SICH), death and other serious adverse events. RESULTS 54 patients (25 IAT) were enrolled. Median time from stroke onset to start to treatment was 3 h 15 min for IAT and 2 h 35 min for IVT (p<0.001). Almost twice as many patients on IAT as those on IVT survived without residual disability (12/25 vs 8/29; OR 3.2; 95% CI 0.9 to 11.4; p=0.067). SICH occurred in 2/25 patients on IAT and in 4/29 on IVT (OR 0.5; CI 0.1 to 3.3; p=0.675). Mortality at day 7 was 5/25 (IAT) compared with 4/29 (IVT) (OR 1.6; CI 0.4 to 6.7; p=0.718). There was no significant difference in the rate of other serious adverse events. CONCLUSIONS Rapid initiation of IAT is a safe and feasible alternative to IVT in acute ischemic stroke.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Acidente Vascular Cerebral/tratamento farmacológico , Terapia Trombolítica/métodos , Ativador de Plasminogênio Tecidual/administração & dosagem , Idoso , Isquemia Encefálica/mortalidade , Estudos de Viabilidade , Feminino , Seguimentos , Humanos , Infusões Intra-Arteriais , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Acidente Vascular Cerebral/mortalidade , Taxa de Sobrevida/tendências , Fatores de Tempo , Resultado do Tratamento
11.
Bone Marrow Transplant ; 42 Suppl 2: S2-6, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18978739

RESUMO

Nowadays, different treatment options are available for an extending list of lysosomal storage diseases (LSDs). Hematopoietic stem cell transplantation (HSCT) can benefit selected subsets of patients with some LSDs, but results have been poor in several other disorders, including metachromatic leukodystrophy (MLD), outlining the need for innovative therapeutic approaches in this field. Enzyme replacement therapy has been developed recently for MLD, and a Phase I/II trial is ongoing. However, the blood-brain barrier limits the access of the recombinant product to the nervous tissues. Autologous hematopoietic stem/progenitor cells can be genetically modified to constitutively express supra-physiological levels of arylsulfatase-A and may become a quantitatively more effective source of functional enzyme than normal donor cells when transplanted in patients with MLD, thus possibly overcoming the limits of HSCT. Moreover, autologous transplantation might be associated with a significantly reduced transplant-related morbidity and TRM avoiding the risk of GVHD. Therefore, such a gene therapy strategy could represent a significant advance in comparison to conventional allogeneic HSCT.


Assuntos
Cerebrosídeo Sulfatase/uso terapêutico , Terapia Genética , Transplante de Células-Tronco Hematopoéticas , Leucodistrofia Metacromática/terapia , Proteínas Recombinantes/uso terapêutico , Barreira Hematoencefálica/enzimologia , Ensaios Clínicos Fase I como Assunto , Ensaios Clínicos Fase II como Assunto , Terapia Genética/tendências , Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas/tendências , Humanos , Leucodistrofia Metacromática/enzimologia , Fatores de Risco , Transplante Autólogo , Transplante Homólogo
12.
J Med Genet ; 34(11): 889-92, 1997 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9391880

RESUMO

We report two patients with suspected hereditary liability to pressure palsies. Neurophysiological studies showed a mixed axonal-demyelinating sensory-motor polyneuropathy with focal slowing of conduction velocities at the common sites of entrapment. Morphological studies on sural nerve biopsy from the proband showed active axonal regeneration without typical tomacula. Molecular analysis confirmed the presence of a deletion of chromosome 17p11.2 in both patients. Our observation confirms the heterogeneity of hereditary liability to pressure palsies and the relevance of DNA testing for the diagnosis of this hereditary neuropathy.


Assuntos
DNA/análise , Neuropatia Hereditária Motora e Sensorial/genética , Adolescente , Southern Blotting , Cromossomos Humanos Par 17 , Feminino , Testes Genéticos , Neuropatia Hereditária Motora e Sensorial/diagnóstico , Neuropatia Hereditária Motora e Sensorial/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Linhagem , Reação em Cadeia da Polimerase
15.
Pathologica ; 87(6): 650-2, 1995 Dec.
Artigo em Italiano | MEDLINE | ID: mdl-8927425

RESUMO

The location of reserve cells make it possible the understanding of cervicovaginal repair by metaplasia process better, really some have studied the potentiality of such cells. Now we believe that totipotent stromal cell, which can evolve towards the epithelial cells, give origin to reserve cells. Immunohistochemistry methods point out stain positively for cytokeratin (DW 45-56,5 KD) present in reserve cells, confirmed the stromal origin of them.


Assuntos
Colo do Útero/citologia , Células do Tecido Conjuntivo , Queratinas/análise , Adulto , Biomarcadores , Diferenciação Celular , Movimento Celular , Células Epiteliais , Feminino , Fibroblastos/citologia , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade
16.
Radiol Med ; 90(3): 187-93, 1995 Sep.
Artigo em Italiano | MEDLINE | ID: mdl-7501820

RESUMO

This study was aimed at assessing the MR patterns of transient osteoporosis of the hip and, consequently, the role of MRI in the diagnosis and follow-up of this condition. Even though this condition was originally observed in pregnant women, young or middle-aged men are most frequently affected. There is a spontaneous onset of pain, usually progressing over several weeks. The patients have no risk factors for osteonecrosis; they may have a history of minor trauma and there is a possible relationship to the third trimester of pregnancy. Laboratory values are negative. Pain may be severe enough to cause the patient to limp and to impair joint function. The possible causes of transient osteoporosis have been debated by many authors and include trauma, synovitis, neurovascular dysfunction and transient or reversible ischemia. Transient osteoporosis is a self-limiting disease which does not require surgical treatment. The differential diagnosis of transient osteoporosis of the hip is very important because this condition may simulate cancer, septic arthritis, osteomyelitis or avascular necrosis. We report the initial and follow-up features of transient osteoporosis of the hip on the MR images of 6 patients (M/F = 5/1; age: 37-49 years, mean: 41.8 years). The right side was involved in 3 patients, the left side in 2 patients. The patient with bilateral transient osteoporosis was a woman in the 3rd trimester of pregnancy. In all patients, MRI was performed with an 0.5 T MR unit. The MR changes in our 6 patients were rather uniform and included heterogeneous decrease in the signal intensity of the affected bone marrow on T1-weighted images and increased signal intensity on T2-weighted and STIR images, with no evidence of focal lesions. This pattern is known as the "bone marrow edema" (BME) pattern. All the patients received conservative treatment. The clinical symptoms and the MR abnormalities regressed completely within 6-10 months, with no late sequelae. To conclude, this follow-up MR study demonstrates the transient, reversible character of transient osteoporosis of the hip. Until the natural history of the BME pattern is better understood, we suggest a conservative management of this condition, especially in the patients with no risk factors for osteonecrosis. Radiographic and MR follow-up is recommended.


Assuntos
Articulação do Quadril/patologia , Imageamento por Ressonância Magnética , Osteoporose/diagnóstico , Adulto , Doenças da Medula Óssea/diagnóstico , Doença Crônica , Edema/diagnóstico , Feminino , Seguimentos , Articulação do Quadril/diagnóstico por imagem , Humanos , Imageamento por Ressonância Magnética/instrumentação , Imageamento por Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Radiografia
18.
J Neurol Sci ; 128(1): 36-44, 1995 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-7722532

RESUMO

The difference in the lifespan of dy and mdx mice could be due to different muscle regeneration capabilities. In mdx an involvement of bFGF in stimulating regeneration has been postulated. The aim of our work was to detect the presence, and to study the distribution, of muscular and connective tissue growth factors in mdx and dy mice at different stages of muscle pathology. From 7 to 10 weeks of age the difference between the two dystrophic mice becomes evident. At 13 weeks the dy mouse presents a predominance of fibrosis and degenerative muscular phenomena while the main pathological feature in mdx mouse is the muscle regeneration. In both animal models fibrosis proliferation is correlated to the presence of EGF and its receptor and TGF beta 1. bFGF was localized to regenerating and degenerating fibers in both dy and mdx mice. The bFGF presented a normal pattern in mdx mice at 20 weeks when regenerative and degenerative phenomena were no longer present. Our data suggest that growth factors could influence the outcome of muscular regenerative and degenerative processes.


Assuntos
Tecido Conjuntivo/metabolismo , Substâncias de Crescimento/metabolismo , Distrofias Musculares/metabolismo , Animais , Tecido Conjuntivo/patologia , Fator de Crescimento Epidérmico/metabolismo , Receptores ErbB/metabolismo , Fator 2 de Crescimento de Fibroblastos/metabolismo , Fibrose/metabolismo , Fibrose/patologia , Imuno-Histoquímica , Linfotoxina-alfa/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Músculos/patologia , Distrofias Musculares/genética , Distrofias Musculares/patologia
19.
Radiol Med ; 89(1-2): 130-5, 1995.
Artigo em Italiano | MEDLINE | ID: mdl-7716293

RESUMO

Aplastic anemia is a rare hematologic disorder characterized by hypocellular fatty marrow. Aplastic anemia is diagnosed on the basis of laboratory tests and bone marrow biopsy findings. Biopsy is of fundamental importance for bone marrow assessment, though not representative of the rest of the marrow. Thanks to its exclusive capabilities in the direct visualization of bone marrow, MRI is a noninvasive and relatively rapid method for bone marrow study. The authors report their experience in 3 aplastic anemia patients examined also with MRI at presentation and after marrow transplantation. The dorsolumbar spine was studied with sagittal SE T1-weighted and STIR sequences, while pelvic bones were investigated only with SE T1-weighted sequences in all patients. Two of them were also examined with sagittal scans of the dorsolumbar spine using the chemical shift fat suppression technique. In all three patients, SE T1-weighted images at presentation showed fatty bone marrow infiltration, also confirmed on fat suppression images, and, after transplantation, progressive bone marrow repopulation, with the typical "band" pattern in vertebral marrow. Although MR specificity remains low in the demonstration of bone marrow disorders, the authors believe it to be a useful tool, after accurate clinical and laboratory exams, not only in the diagnosis but also and especially in the follow-up of these disorders.


Assuntos
Anemia Aplástica/diagnóstico , Anemia Aplástica/terapia , Transplante de Medula Óssea , Medula Óssea/patologia , Adulto , Anemia Aplástica/patologia , Feminino , Seguimentos , Humanos , Masculino , Ossos Pélvicos/patologia , Coluna Vertebral/patologia , Fatores de Tempo
20.
Andrologia ; 26(4): 241-5, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-7526746

RESUMO

Effects of short-term high-dose testosterone propionate treatment on medium molecular-weight proteins (lactoferrin, albumin, prostatic acid phosphatase, prostate specific antigen) and on zinc and fructose levels were investigated in the seminal plasma of seven normal volunteers. A significant reduction in levels of prostatic-acid phosphatase, zinc and, to a lesser degree, prostate-specific antigen, lactoferrin and fructose was observed on the 14th day of androgen treatment, concomitantly with the maximal increase in free androgen-circulating levels. The data obtained suggest that testosterone administration may induce a reduction in the sex accessory-gland secretion. Indeed, this effect tends to disappear with withdrawal of hormone treatment. Therefore, the authors suggest a close follow-up of prostatic and vesicular function during the long-term high-dose testosterone intake, used frequently as anabolic treatment by athletes and body builders.


Assuntos
Proteínas Secretadas pela Próstata , Proteínas/metabolismo , Sêmen/metabolismo , Testosterona/farmacologia , Fosfatase Ácida/metabolismo , Adolescente , Adulto , Albuminas/metabolismo , Di-Hidrotestosterona/sangue , Frutose/metabolismo , Humanos , Isoenzimas/metabolismo , Lactoferrina/metabolismo , Masculino , Próstata/enzimologia , Antígeno Prostático Específico/metabolismo , Proteínas/isolamento & purificação , Radioimunoensaio , Sêmen/efeitos dos fármacos , Proteínas de Plasma Seminal , Testosterona/sangue , Zinco/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA